Granules India Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹20.9K Cr
Granules India anticipates meaningful revenue growth driven by launches of 3-4 complex generic products, including CNS, ADHD, and controlled substances, within the next 1 to 1.5 years. - Launch of 1-2 existing products from the Genome Valley facility over the next 1-2 quarters to cater to additional demand, with incremental revenue expected. - Continued focus on complex generics such as oncology, CNS, and controlled substances, contributing to a larger share of filings and revenues. - Growth in the U.S. Granules India expects meaningful growth from 3-4 product launches within the next 1 to 1.5 years, particularly in complex generics like CNS, ADHD, and controlled substances.
From Granules India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹858
Market Cap
₹20.9K Cr
P/E Ratio
32.2
How does Granules India Ltd rank in Pharmaceuticals & Biotechnology?
Compare Granules India Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Granules India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.5K Cr, net profit ₹202 Cr.
Full financials →📊 Revenue & Sales Performance
- →Granules India anticipates meaningful revenue growth driven by launches of 3-4 complex generic products, including CNS, ADHD, and controlled substances, within the next 1 to 1.5 years.
- →Launch of 1-2 existing products from the Genome Valley facility over the next 1-2 quarters to cater to additional demand, with incremental revenue expected.
- →Continued focus on complex generics such as oncology, CNS, and controlled substances, contributing to a larger share of filings and revenues.
- →Growth in the U.S. market via early generic launches for limited competition products like lisdexamfetamine and generic Adzenys with significant market share potential.
- →Steady expansion supported by operational efficiencies and increased capacity utilization at Gagillapur and GLS sites.
- →Expected sequential improvement in sales and margins in core and new products, including ramp-up in peptide and CRAMS business.
- →Long-term aspiration to add $40-50 million annually to U.S. revenues, reflecting strong growth trajectory.
📈 Profitability & Margins
- →Granules India expects meaningful growth from 3-4 product launches within the next 1 to 1.5 years, particularly in complex generics like CNS, ADHD, and controlled substances.
- →Controlled substances such as amphetamine are strategically important, likely contributing significantly to earnings due to limited competition and early market entry.
- →Expansion and approvals at the Genome Valley facility will drive incremental revenue in FY27, with 1-2 product launches expected in the next two quarters.
- →The company aims for steady EBITDA margin improvement through an increased share of complex generics and formulation sales mix.
- →Operational efficiencies and capacity utilization improvements, especially post-remediation at Gagillapur and scaling at GLS, will support earnings growth.
- →The peptide CDMO business is expected to improve to breakeven and positive EBITDA in Q4 FY26, contributing positively going forward.
- →The management is confident of adding $40-50 million to US revenues annually in coming years, supporting growth.
🏗️ Capital Expenditure Plans
- →Granules is investing in system enhancements involving capex and opex over upcoming quarters to strengthen operational reliability and resilience.
- →Expansion plans include capacity expansion supported by proceeds from a recent preferential issue aimed at enhancing financial flexibility.
- →New plants, including an API plant in Vizag with advanced automation (DCS-driven, paperless documentation), are under development.
- →Continued focus on digitalization and automation, especially at Gagillapur (implementation expected by mid-calendar year), to improve quality and compliance.
- →Investment will also support scaling operations at GLS facility as regulatory milestones are achieved.
- →Ongoing investments in R&D to support long-term strategic growth, sustaining 5% of sales in R&D expenses.
- →Strategic capital employed prudently to pursue value-accretive opportunities while maintaining governance and capital discipline.
💰 Fundraising & Capital Structure
- →In the Q3 FY26 earnings call, Granules India Limited recently completed a **preferential equity issue** with strong shareholder support, enhancing financial flexibility.
- →The proceeds from this preferential issue are intended to support **capacity expansion, drive efficiency, and pursue value-accretive opportunities**, while maintaining capital discipline.
- →There was no mention of any **imminent or future fundraising through debt** during the call.
- →The company emphasized prudent deployment of the preferential issue proceeds rather than announcing new debt or equity raises.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Granules India's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Granules India Ltd Q3 FY26 results?
Granules India anticipates meaningful revenue growth driven by launches of 3-4 complex generic products, including CNS, ADHD, and controlled substances, within the next 1 to 1.5 years. - Launch of 1-2 existing products from the Genome Valley facility over the next 1-2 quarters to cater to additional demand, with incremental revenue expected. - Continued focus on complex generics such as oncology, CNS, and controlled substances, contributing to a larger share of filings and revenues. - Growth in the U.S. Granules India expects meaningful growth from 3-4 product launches within the next 1 to 1.5 years, particularly in complex generics like CNS, ADHD, and controlled substances.
What is Granules India Ltd share price analysis?
Granules India Ltd currently shows a neutral. The stock trades at a P/E of 32.2 with a market cap of ₹20,941 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India Ltd planning capital expenditure?
Granules is investing in system enhancements involving capex and opex over upcoming quarters to strengthen operational reliability and resilience.
Keep Granules India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.